Accès gratuit
Editorial
Numéro
Med Sci (Paris)
Volume 26, Numéro 2, Février 2010
Page(s) 115 - 118
Section Éditorial
DOI https://doi.org/10.1051/medsci/2010262115
Publié en ligne 15 février 2010
  1. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346 : 1185–93. [Google Scholar]
  2. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360 : 447–58. [Google Scholar]
  3. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12 : 401–9. [Google Scholar]
  4. Leboulch P and the LentiGlobin clinical trial study group. Conversion to transfusion independence with partial clonal dominance after lentiviral gene therapy for severe human beta-thalassemia (abstract). Hum Gene Ther 2009; 20 : 1369–70. [Google Scholar]
  5. Boztug K, Schmidt M, Schwarzer A, et al. HSC gene therapy in two WAS patients (abstract). Hum Gene Ther 2009; 20 : 1371. [Google Scholar]
  6. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006; 12 : 1397–402. [Google Scholar]
  7. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010 (sous presse). [Google Scholar]
  8. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326 : 818–23. [Google Scholar]
  9. Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. Blood 2009; 114 : 3524–32. [Google Scholar]
  10. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118 : 3132–42. [Google Scholar]
  11. Dykstra B, Kent D, Bowie M, et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 2007; 1 : 218–29. [Google Scholar]
  12. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364 : 2181–7. [Google Scholar]
  13. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118 : 3143–50. [Google Scholar]
  14. Kelly PF, Radtke S, von Kalle C, et al. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 2007; 15 : 211–9. [Google Scholar]
  15. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009; 15 : 285–92. [Google Scholar]
  16. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial) : a non-randomised phase I-II study. Lancet Oncol 2009; 10 : 489–500. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.